Exane Derivatives Biogen Inc. Transaction History

Exane Derivatives

$157 Million
Q2 2022

A detailed history of Exane Derivatives transactions in Biogen Inc. stock. As of the latest transaction made, Exane Derivatives holds 1 shares of BIIB stock, worth $149. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 1 -0.0%

Holding current value

$149

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 28, 2022	SELL	$223.92 - $287.77 $82,626 - $106,187	-369 Reduced 99.73%	1 $0
Q3 2021 Oct 26, 2021	BUY	$282.99 - $369.05 $104,423 - $136,179	369 Added 36900.0%	370 $104,000
Q2 2021 Jul 28, 2021	SELL	$259.0 - $414.71 $2,331 - $3,732	-9 Reduced 90.0%	1 $0
Q3 2020 Oct 06, 2020	SELL	$264.77 - $305.71 $374,649 - $432,579	-1,415 Reduced 99.3%	10 $2,000
Q2 2020 Jul 10, 2020	BUY	$258.66 - $342.55 $365,227 - $483,680	1,412 Added 10861.54%	1,425 $381,000
Q4 2019 Jan 22, 2020	SELL	$220.06 - $304.07 $327,009 - $451,848	-1,486 Reduced 99.13%	13 $3,000
Q2 2019 Jul 12, 2019	SELL	$219.29 - $241.72 $218,851 - $241,236	-998 Reduced 39.97%	1,499 $0
Q1 2019 Apr 24, 2019	BUY	$216.71 - $338.96 $474,378 - $741,983	2,189 Added 710.71%	2,497 $0
Q4 2018 Jan 31, 2019	BUY	$278.5 - $352.75 $37,597 - $47,621	135 Added 78.03%	308 $92,000
Q3 2018 Oct 24, 2018	SELL	$293.51 - $383.83 $88,640 - $115,916	-302 Reduced 63.58%	173 $0
Q2 2018 Jul 19, 2018	SELL	$257.52 - $306.91 $401,731 - $478,779	-1,560 Reduced 76.66%	475 $0
Q1 2018 Apr 30, 2018	BUY	$260.13 - $367.91 $336,348 - $475,707	1,293 Added 174.26%	2,035 $0
Q4 2017 Jan 29, 2018	BUY	$307.64 - $344.58 $9,844 - $11,026	32 Added 4.51%	742 $0
Q3 2017 Oct 18, 2017	BUY	$281.15 - $329.69 $199,616 - $234,079	710	710 $0

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Account

Exane Derivatives Biogen Inc. Transaction History